Learn More
5009 Background:  Options for women with recurrent endometrial cancer (EC) are limited. Clinical studies suggest mTOR inhibitors such as R have activity in this disease. This trial evaluated activity(More)
PURPOSE Paclitaxel, docetaxel, and vinorelbine have been approved for chemotherapy in patients with advanced breast cancer that is resistant to anthracyclines. Selecting which agent to use is(More)